Globus Medical
GMED
$70.50
-2.27%
Globus Medical is a medical device company that designs and sells musculoskeletal implants and instruments used primarily in spinal and orthopedic procedures, alongside a smaller 'enabling technologies' franchise of surgical navigation, robotics, and imaging systems. It is a top-tier challenger in the roughly $10B+ global spine implant market, historically distinguished by rapid product cadence, a direct-to-surgeon sales model, and its ExcelsiusGPS robotic platform, though the 2023 NuVasive merger transformed it into a scaled #2 player with a broader portfolio and international footprint. The current investor debate centers on post-merger integration and growth durability: the Q3 2026 print (filed November 5) featured a revenue miss, a cut to 2026 guidance, and management's framing of a '2027 reset,' which has reignited questions about spine market share, pricing pressure, and whether the combined entity can reaccelerate revenue after a year of essentially flat top-line performance. Sentiment is further complicated by the stock's persistent underperformance versus the medtech group and the S&P 500, leaving investors weighing a cheap-looking forward multiple against execution risk.…
GMED
Globus Medical
$70.50
Related headlines
Investment Opinion: Should I buy GMED Today?
Rating: Hold, with a constructive bias toward accumulating on stabilization. The core thesis is that GMED is a high-quality, cash-generative spine franchise trading at a historically depressed 13.5x forward earnings and 4.0x sales, where the entire debate reduces to whether the consensus 2027 EPS of $7.46 materializes — and at $72.14 versus a $93.43 average analyst target (10 Buy / 5 Hold / 0 Sell, mean rating 1.93), the Street is paying for patience but not yet for proof.
The supporting evidence is genuinely strong on quality and cheap on price: gross margin expanded to 69.5% from 63.3% a year earlier, operating margin to 23.2% from 17.6%, and EBITDA margin reached 33.2% ($253.6M), while trailing free cash flow of $756.6M and a debt-to-equity of 0.026 with $487.7M cash give management the ability to buy back $142.9M of stock per quarter without leverage. Valuation is the anchor — 21.9x trailing compresses to 13.5x forward (a 38% step-down), EV/EBITDA of 12.8x and EV/Sales of 2.91x sit below typical large-cap medtech levels, and PS of 4.0x is near the bottom of a 10x-27x band since 2022. The offsetting evidence is that revenue fell 0.69% year-over-year to $763.7M, guidance was cut, and the stock is down 16.02% over three months with a -26.38 relative strength versus the S&P 500 over twelve months — so the cheap multiple is currently being earned, not gifted.
The biggest risks that could invalidate the thesis are (1) a second consecutive guidance cut that confirms the 2027 reset is slipping, (2) continued spine pricing pressure with Emerging Technology at just $28.0M of $763.7M revenue unable to offset it, and (3) multiple compression if estimates fall faster than the stock. This Hold would upgrade to Buy if revenue returns to positive year-over-year growth and management reaffirms the 2027 EPS bridge, or if the shares hold the $70.40 52-week low and reclaim the $81-$82 post-earnings gap; it would downgrade to Sell on a break below $70.40 accompanied by another estimate cut. Verdict: undervalued relative to its own history and modestly discounted to peers, but fairly-to-fully valued relative to the near-term earnings trajectory — a value opportunity only for investors who can underwrite execution risk.
Sign up to view all
GMED 12-Month Price Forecast
GMED presents a classic cheap-for-a-reason setup: the 13.5x forward multiple and 4.0x sales are near multi-year lows, but they are discounting flat revenue, a guidance cut, and a 2027 recovery that management has promised rather than demonstrated. The quality of the franchise is not in question — 69.5% gross margins, 33.2% EBITDA margins, $756.6M trailing free cash flow, and near-zero leverage are genuinely strong — but margins are expanding on cost discipline while the top line stalls, which caps how far EPS can grow without a revenue inflection. The analyst community is in 'wait for proof' mode: 10 of 14 rate Buy with a $93.43 average target, yet BMO downgraded on November 6 and the $75-$110 spread signals real disagreement about the recovery path. We would upgrade to bullish on evidence of positive year-over-year revenue growth and a reaffirmed 2027 EPS bridge, and downgrade to bearish on a break below the $70.40 low accompanied by another estimate cut. Until then, the risk/reward is asymmetric only for patient investors willing to underwrite execution at a historically depressed multiple.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Globus Medical's 12-month outlook, with a consensus price target around $93.43 and implied upside of +32.5% versus the current price.
Average Target
$93.43
15 analysts
Implied Upside
+32.5%
vs. current price
Analyst Count
15
covering this stock
Price Range
$75 - $110
Analyst target range
Coverage is solid, with 14 analysts and a distribution of 10 Buy, 5 Hold, and 0 Sell, yielding a consensus recommendation of 'buy' (mean rating 1.93 on a 1-5 scale). The average target price is $93.43, which implies roughly +29.5% upside from the current $72.14 — a wide gap that reflects how far the stock has fallen below where the Street's models sit. The consensus leans bullish, but the post-earnings actions tell a more nuanced story: BMO Capital downgraded to Market Perform from Outperform on November 6, while Truist, Needham, Wells Fargo, and Canaccord reiterated Buy/Overweight ratings, suggesting analysts are defending the long-term thesis even as near-term estimates come down.
The target range of $75.00 to $110.00 is wide — a spread of about 47% around the average — signaling genuine uncertainty about the 2027 recovery path. The high target of $110 assumes multiple expansion back toward historical medtech-premium levels, successful NuVasive integration, and a return to double-digit revenue growth with robotics (ExcelsiusGPS) driving share gains. The low target of $75, barely above the current price, prices in continued spine market pressure, margin compression from pricing, and a delayed or underwhelming 2027 reset. The clustering of recent reiterations at Buy alongside a single downgrade and a Hold from Stifel suggests the Street is in 'wait for proof' mode — conviction is moderate, and the wide dispersion means the stock is likely to remain volatile around each quarterly print until the revenue trajectory visibly inflects.
Bulls vs Bears: GMED Investment Factors
The bear case currently carries stronger near-term evidence: revenue is flat to down (-0.69% YoY), guidance was cut, the stock sits 1.7 points off its 52-week low with accelerating downside momentum, and it has lagged the S&P 500 by 26 points over twelve months. The bull case rests on valuation and quality rather than momentum — a 13.5x forward PE, 69.5% gross margins, 33.2% EBITDA margins, $756.6M trailing FCF, near-zero leverage, and a 10-Buy/5-Hold/0-Sell consensus with a $93.43 average target implying 29.5% upside. The single most important tension is whether the '2027 reset' is a genuine inflection or another slipping promise: if the $7.46 consensus 2027 EPS materializes, the forward multiple is cheap and the stock re-rates; if guidance slips again, the forward number is a value trap and the 52-week low of $70.40 likely breaks. Until revenue visibly inflects, the risk/reward is asymmetric only for patient investors willing to underwrite execution risk at a historically depressed multiple.
Bullish
- Forward PE of 13.5x looks deeply discounted: GMED trades at 21.9x trailing but only 13.5x forward earnings, a 38% compression that implies the Street's 2027 EPS estimate of $7.46 is roughly double the current run-rate. If the '2027 reset' delivers even partially, the forward multiple is among the cheapest in large-cap medtech, where peers typically command high-teens to low-20s forward multiples.
- Margins expanding despite flat revenue: Q3 2026 gross margin rose to 69.5% from 63.3% a year earlier, operating margin jumped to 23.2% from 17.6%, and net margin expanded to 18.5% from 15.5%. EBITDA of $253.6M equates to a 33.2% EBITDA margin, showing the NuVasive combination is generating real cost and mix synergies even before revenue inflects.
- Fortress balance sheet and strong cash generation: Debt-to-equity is just 0.026, the current ratio is 4.26, and cash stood at $487.7M at quarter-end. Trailing free cash flow of $756.6M and Q3 FCF of $224.8M ($265.2M operating cash flow less $40.4M capex) fund $142.9M of quarterly buybacks without leverage, giving management ample optionality.
- Analyst consensus Buy with 29.5% implied upside: Of 14 analysts, 10 rate Buy, 5 Hold, and 0 Sell, yielding a mean rating of 1.93 and an average target of $93.43 versus the $72.14 price. Truist, Needham, Wells Fargo, and Canaccord reiterated Buy/Overweight post-earnings, signaling the Street is defending the long-term thesis even as near-term estimates come down.
Bearish
- Revenue has stalled outright: Q3 2026 revenue of $763.7M was down 0.69% year-over-year versus $769.0M, and the sequential path ($759.9M Q1, $789.6M Q2, $763.7M Q3) shows no momentum. Management cut 2026 guidance and framed a '2027 reset,' effectively conceding no near-term reacceleration.
- Extreme concentration in pressured spine market: Spine generated $741.0M of Q3's $763.7M revenue while Emerging Technology contributed just $28.0M (under 4%). The entire franchise hinges on a mature, price-pressured spinal implant market, and the robotics optionality that once justified a premium is too small to move the needle.
- Falling-knife technical profile: At $72.14 the stock sits just 1.7 points above its 52-week low of $70.40, only ~7% of the 52-week range, with a -26.62% max drawdown. It is down 16.02% over three months versus 5.87% over six months, meaning the decline is accelerating, and the November 6 post-earnings 13% gap from $81.44 to $71.05 shows no capitulation reversal yet.
- Severe relative underperformance: GMED is down 14.11% over one year and 17.37% YTD against the S&P 500's +12.27% and +10.62%, producing a relative strength of -26.38 over twelve months. Persistent distribution versus the medtech group and the index reflects a de-rating that has not yet found a floor.
GMED Technical Analysis
Globus Medical is in a sustained, multi-quarter downtrend rather than a consolidation. The stock is down 14.11% over the past year and 17.37% year-to-date, badly lagging the S&P 500's +12.27% 1-year and +10.62% YTD returns, producing a relative strength of -26.38 over twelve months. At $72.14, the shares sit just 1.7 points above the 52-week low of $70.40 and roughly 29% below the 52-week high of $101.40 — translating to about 7% of the 52-week range, a positioning that signals persistent distribution and a 'falling knife' profile rather than an oversold bounce candidate. The maximum drawdown of -26.62% confirms the severity of the de-rating.
Short-term momentum is decisively negative and accelerating to the downside. The stock is down 5.46% over one month and 16.02% over three months, meaning the recent leg lower is steeper than the 5.87% six-month decline — momentum is deteriorating, not stabilizing. The November 6 post-earnings session is the tell: shares gapped from $81.44 to $71.05 in a single day (a roughly 13% drop) on heavy volume after the guidance cut, and follow-through selling pushed the price to $72.14 by November 13. This is a classic post-guidance-cut breakdown with no evident capitulation reversal; the 1-month (-5.46%) versus 1-year (-14.11%) relationship shows the decline is front-loaded into the recent news rather than a slow bleed, which raises the odds of further volatility before a base forms.
Key technical levels are now well defined. Support sits at the 52-week low of $70.40 — a break below that level would confirm a fresh leg lower and likely trigger momentum-driven selling toward uncharted territory, while a hold and reclaim of the $75-$76 area (the pre-earnings congestion zone) would be the first sign of stabilization. Resistance is layered: the $81-$82 breakdown gap from November 6 is the immediate ceiling, with the $88-$101 region (the August highs near $88.34 and the 52-week high of $101.40) representing the full recovery hurdle. With a beta of 0.951, GMED is slightly less volatile than the market on a trailing basis, but that statistic understates event risk here — the single-day 13% gap shows idiosyncratic, news-driven volatility that position sizing must account for regardless of the low beta.
Beta
0.95
0.95x market volatility
Max Drawdown
-27.2%
Largest decline past year
52-Week Range
$70-$101
Price range past year
Annual Return
-16.5%
Cumulative gain past year
| Period | GMED Return | S&P 500 |
|---|---|---|
| 1m | -8.1% | -3.0% |
| 3m | -18.4% | -3.6% |
| 6m | -16.1% | -0.2% |
| 1y | -16.5% | +10.1% |
| ytd | -19.2% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GMED Fundamental Analysis
The revenue trajectory has stalled. Q3 2026 revenue of $763.7M was down 0.69% year-over-year versus $769.0M in Q3 2025, and the sequential path ($759.9M in Q1, $789.6M in Q2, $763.7M in Q3) shows no growth momentum. Segment disclosure underscores the concentration risk: Spine generated $741.0M of the quarter's revenue while Emerging Technology contributed just $28.0M, so the entire franchise hinges on a mature, price-pressured spinal implant market. Management's guidance cut and '2027 reset' commentary imply the company does not expect a near-term reacceleration, which undermines the post-NuVasive synergy thesis and is the core reason the stock has de-rated.
Profitability, by contrast, remains solid and is actually improving. Q3 2026 net income was $141.2M (18.5% net margin) on gross margin of 69.5%, up from 63.3% gross margin and a 15.5% net margin in Q3 2025 — a meaningful year-over-year expansion driven by favorable mix and cost discipline. Operating margin reached 23.2% in Q3 versus 17.6% a year earlier, and EBITDA of $253.6M equates to a 33.2% EBITDA margin. The tension in the story is that margins are expanding while revenue is flat to down, which is a recipe for earnings quality questions: cost cuts and mix can only carry EPS so far without top-line growth.
The balance sheet is a fortress and cash generation is strong. Debt-to-equity is just 0.026, the current ratio is 4.26, and cash stood at $487.7M at quarter-end; trailing free cash flow is $756.6M, and Q3 operating cash flow of $265.2M against capex of $40.4M produced $224.8M of quarterly FCF. ROE is 11.8% and ROA 8.8% — respectable but not exceptional for a medtech with this leverage profile. The company is clearly self-funding, returning capital via $142.9M of buybacks in Q3 alone, but the very low leverage also means the balance sheet is not being used to accelerate growth — a strategic choice investors may increasingly question if the top line stays flat.
Quarterly Revenue
$763719000.0B
2026-09
Revenue YoY Growth
-0.7%
YoY Comparison
Gross Margin
69.5%
Latest Quarter
Free Cash Flow
$756550000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GMED Overvalued?
Because net income is positive ($141.2M in Q3), the PE ratio is the appropriate primary metric. GMED trades at 21.9x trailing earnings but only 13.5x forward earnings — a striking 38% compression that implies the market expects a sharp EPS step-up, consistent with the consensus 2027 EPS estimate of $7.46 versus the current run-rate. That gap is the crux of the debate: if the '2027 reset' delivers, the forward multiple is cheap; if guidance slips again, the forward number is a value trap. On EV/EBITDA of 12.8x and EV/Sales of 2.91x, the stock is not expensive in absolute terms.
Relative to the medical devices sector, GMED screens at a discount on most measures. A 21.9x trailing PE and 13.5x forward PE compare favorably to the high-teens-to-low-20s forward multiples typical of large-cap medtech, while the 4.0x PS and 2.91x EV/Sales are modest for a company with 69.5% gross margins and 23% operating margins. The PEG ratio of 0.05 is optically extreme and should be treated with caution given the depressed earnings base, but the direction is clear: the market is pricing GMED as a low-growth, execution-challenged spine company rather than a premium robotics-enabled medtech. That discount is arguably justified by the flat revenue and guidance cut, but it also embeds little optimism.
Historically, GMED has traded at far richer multiples. Its PS ratio has ranged from roughly 10x to over 27x since 2022, and its trailing PE touched 33x as recently as Q1 2025; today's 4.0x PS and 21.9x PE sit near the bottom of that multi-year band. The current 2.58x price-to-book is also well below the 3-4x levels seen in 2022-2023. This places the stock near historical valuation lows, which can signal either a genuine value opportunity if the 2027 recovery materializes, or fundamental deterioration if the spine market and integration issues prove structural — the evidence so far (flat revenue, guidance cut) leans toward the latter being the risk investors must underwrite.
PE
21.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~121x
vs. Industry Avg
26.4x
Industry PE ~26.4x*
EV/EBITDA
12.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on a stalled top line and concentration. Q3 2026 revenue fell 0.69% year-over-year to $763.7M, and Spine accounted for $741.0M of that total while Emerging Technology contributed just $28.0M, so the franchise is almost entirely dependent on a mature, price-pressured spinal implant market. The margin expansion (gross margin 69.5% vs. 63.3% a year earlier, operating margin 23.2% vs. 17.6%) is being driven by cost discipline and mix rather than volume, which limits how far EPS can grow without revenue recovery and raises earnings-quality questions if the 2027 reset slips. The balance sheet itself is not a risk — debt-to-equity of 0.026, current ratio of 4.26, $487.7M cash, and $756.6M trailing FCF — but the very low leverage means the company is not using its capacity to accelerate growth, a strategic choice investors may question if the top line stays flat. Market and competitive risks are dominated by valuation compression and execution credibility. At 21.9x trailing and 13.5x forward earnings, GMED already trades at a discount to large-cap medtech peers, but the discount is arguably justified by flat revenue and a guidance cut, so further estimate reductions could compress the multiple again rather than expand it. The November 6 BMO downgrade to Market Perform, the wide $75-$110 analyst target spread (roughly 47% around the $93.43 average), and the post-earnings 13% single-day gap from $81.44 to $71.05 illustrate how news-driven and idiosyncratic the volatility is, despite a beta of 0.951 that understates event risk. Competitive pressure in spine implants, pricing headwinds, and the possibility that ExcelsiusGPS robotics fails to drive meaningful share gains against larger competitors add structural risk to the recovery narrative. The worst-case scenario is a second consecutive guidance cut at the next print that confirms the 2027 reset is delayed, triggering further analyst downgrades and momentum selling. In that chain, the stock breaks the 52-week low of $70.40 and tests the analyst low target of $75 (already barely above the current price) or below, implying roughly -2% to -10% from $72.14 in the near term and potentially a retest of the -26.62% max drawdown level if the de-rating extends. From the current price, a realistic adverse outcome is a decline toward the $65-$70 zone, or roughly -3% to -10%, with the risk of a deeper leg lower if the revenue trajectory does not stabilize by mid-2027.
FAQ
The most severe risk is execution on the 2027 reset: revenue fell 0.69% year-over-year to $763.7M in Q3 2026, 2026 guidance was cut, and a second consecutive cut would likely invalidate the $7.46 consensus EPS and break the $70.40 52-week low. Second is revenue concentration — Spine generated $741.0M of the $763.7M quarter while Emerging Technology contributed just $28.0M, leaving the franchise almost entirely exposed to a mature, price-pressured spinal implant market where ExcelsiusGPS robotics is too small to offset pricing headwinds. Third is valuation and sentiment risk: despite the discount, the stock has -26.38 relative strength versus the S&P 500 over twelve months, a -26.62% max drawdown, and a wide $75-$110 analyst target spread that signals genuine disagreement, so further estimate reductions could compress the multiple again rather than expand it. Fourth is earnings quality — margins are expanding (gross margin 69.5% vs. 63.3% a year earlier) while revenue is flat, meaning cost discipline and mix, not volume, are carrying EPS, which limits how far earnings can grow without a top-line inflection.
The 12-month forecast splits into a 50% base case of $75-$93.43, a 25% bull case of $93.43-$110, and a 25% bear case of $65-$75. The base case — the most likely outcome — assumes revenue stabilizes in the low-single-digit range through 2027, gross margin holds near 69.5%, and EPS progresses toward but does not fully reach the $7.46 consensus, letting the stock grind back toward the $93.43 average target as the discount narrows. The bull case requires the 2027 reset to prove real, with positive year-over-year revenue growth, NuVasive cross-selling, ExcelsiusGPS placement traction, and a reaffirmed EPS bridge driving a re-rating toward the $110 high target. The bear case assumes a second guidance cut and 2027 guidance below the $4.33B consensus, breaking the $70.40 low and testing the $75 analyst low target or below toward $65-$70. The key assumption behind the base case is that management maintains the 2027 timeline and does not cut guidance again at the Q4 2026 print.
GMED screens as undervalued relative to its own history and modestly discounted to large-cap medtech peers, but fairly-to-fully valued relative to its near-term earnings trajectory. At 21.9x trailing and 13.5x forward earnings, 4.0x sales, 2.91x EV/Sales, and 12.8x EV/EBITDA, the stock sits near the bottom of a multi-year band — its PS ratio ranged roughly 10x-27x since 2022 and its trailing PE touched 33x as recently as Q1 2025, versus 21.9x today. The 38% gap between trailing and forward multiples implies the market expects EPS to roughly double toward the $7.46 consensus, which is precisely what makes the valuation conditional: if the 2027 reset delivers, 13.5x is cheap for a 69.5%-gross-margin medtech; if guidance slips again, the forward number is a value trap. The 0.05 PEG ratio is optically extreme and should be discounted given the depressed earnings base, but the direction is clear — the market is pricing GMED as a low-growth, execution-challenged spine company rather than a premium robotics-enabled medtech.
From a risk/reward perspective, GMED offers roughly 29.5% upside to the $93.43 average analyst target against limited but real downside to the $70.40 52-week low, only about 2.4% below the current $72.14 — an asymmetry that looks favorable on paper but is complicated by the fact that the stock has already broken down 16.02% over three months and sits near the bottom of its range. The quality side of the ledger is strong: 69.5% gross margin, 33.2% EBITDA margin, $756.6M trailing free cash flow, and debt-to-equity of just 0.026, all at a 13.5x forward PE. The catch is that the forward multiple depends on a 2027 EPS step-up to $7.46 that has not been evidenced, and revenue is currently down 0.69% year-over-year with guidance already cut. It is a reasonable buy only for patient, valuation-disciplined investors who can tolerate another quarter or two of volatility and who size positions for the possibility of a retest of the $65-$70 zone; it is not a good buy for momentum or near-term traders.
GMED is better suited to a long-term holding period of at least 18-24 months than to short-term trading, because the thesis hinges on a 2027 earnings reset that will not be resolved within a quarter or two. The stock pays no dividend (0% yield, 0% payout ratio), so total return depends entirely on multiple re-rating and EPS growth rather than income, and its beta of 0.951 understates the event risk — the November 6 post-earnings 13% single-day gap from $81.44 to $71.05 shows how violently idiosyncratic news can move the shares. Earnings visibility is currently low: revenue is flat to down, guidance was cut, and the $75-$110 analyst target spread of roughly 47% around the average reflects genuine uncertainty about the recovery path. Short-term traders face a falling-knife profile — the stock is 5.46% lower over one month and 16.02% lower over three months, with momentum deteriorating rather than stabilizing — while long-term investors can underwrite the 13.5x forward multiple and $756.6M free cash flow against a 2027 recovery, provided they size positions for a possible retest of the $65-$70 zone.

